Clinical trial for Type 1 Diabetes Mellitus
Official title Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose
ClinicalTrials.gov ID: NCT06686329
What this study is testing
- What it's testing
- The study will see whether walking can reduce or prevent high blood sugar that happens when insulin is taken after a meal instead of before it.
- Who it's for
- Adults with type 1 diabetes who use insulin and continuous glucose monitors.
- What's involved
- Participants will give a mistimed insulin dose when their glucose rises, then walk briskly for 15 minutes. Blood sugar will be monitored with a CGM and visits will include brief check‑ins and data collection.
- Time commitment
- The study lasts a few weeks, with several short visits for monitoring and walking sessions after each missed dose.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 24
You may be able to join if
- Adults aged 18-24 years
- Type 1 diabetes diagnostic for at least two years
- Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of \< 9.9%
- Use a Dexcom G7 CGM in routine care
You likely can't join if
- Changes in insulin management strategy within the past 2 months
- Diagnosis of gastroparesis
- Having a condition that could render exercise harmful
- Intolerance to gluten and lactose
- Having significant renal disease (e.g., eGRF \< 30 ml/min)
- Inability to provide informed consent due to cognitive deficit
See the full eligibility criteria
- Adults aged 18-24 years
- Type 1 diabetes diagnostic for at least two years
- Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of \< 9.9%
- Use a Dexcom G7 CGM in routine care
- Changes in insulin management strategy within the past 2 months
- Diagnosis of gastroparesis
- Having a condition that could render exercise harmful
- Intolerance to gluten and lactose
- Having significant renal disease (e.g., eGRF \< 30 ml/min)
- Inability to provide informed consent due to cognitive deficit
- Currently taking other medications (other than insulin) that may alter glucose metabolism (e.g., non-insulin antihyperglycemic drugs such as sglt2-inhibitors, corticosteroids), unless dosages thereof have been stable...
- For women, being pregnant or breastfeeding
The study team makes the final eligibility decision.
Where it is enrolling
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 24 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.